Metreton
Pemphigus, Ophthalmia, Sympathetic, Chorioretinitis + 95 more
Treatment
55 FDA approvals
20 Active Studies for Metreton
Treatment for
Pemphigus
What is Metreton
Prednisone
The Generic name of this drug
Treatment Summary
Diphenhydramine is an antihistamine medication used to treat allergies, hay fever, and asthma. It is commonly used to reduce the symptoms of itching, sneezing, and runny nose. It is less likely to cause drowsiness than other similar medications and is often used in veterinary medicine.
PredniSONE
is the brand name
Metreton Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
PredniSONE
Prednisone
1972
681
Approved as Treatment by the FDA
Prednisone, commonly known as PredniSONE, is approved by the FDA for 55 uses which include Mycosis Fungoides (MF) and Disseminated tuberculosis .
Mycosis Fungoides (MF)
Helps manage Mycosis Fungoides (MF)
Disseminated tuberculosis
Used to treat Disseminated tuberculosis in combination with Aminosalicylic acid
Anemia, Hemolytic
Allergic Rhinitis (AR)
Helps manage Allergic Rhinitis (AR)
Uremia
Thrombocytopenia
Conjunctivitis
Helps manage Ocular Inflammation
Secondary thrombocytopenia
Diuresis
non-suppurative Thyroiditis
Primary adrenocortical insufficiency
Adrenal Cortex Hormones
Helps manage unresponsive to topical corticosteroids
acquired immune hemolytic anemia
Crohn Disease
Helps manage acute Crohn's Disease (CD)
Atopic Dermatitis
Helps manage Atopic Dermatitis
Congenital Hypoplastic Anemia
Congenital Adrenal Hyperplasia (CAH)
Neurologic Involvement
Immune Thrombocytopenia (ITP)
Drug hypersensitivity reaction
Contact Dermatitis
Mycosis Fungoides
Helps manage Mycosis Fungoides (MF)
Thyroiditis
Ulcerative Colitis
Helps manage Ulcerative Colitis
Sarcoidosis
Helps manage symptomatic Sarcoidosis
Secondary adrenocortical insufficiency
Malignant Neoplasms
Stevens-Johnson Syndrome
induction of Diuresis
Idiopathic Nephrotic Syndrome
symptomatic Sarcoidosis
Helps manage symptomatic Sarcoidosis
Asthma
Helps manage Asthma
Ulcerative Colitis
Helps manage Ulcerative Colitis
Ocular Inflammation
Helps manage Ocular Inflammation
Pemphigus
Helps manage Pemphigus
Trichinosis
Pemphigus
Helps manage Pemphigus
Systemic Lupus Erythematosus (SLE)
Adrenal Insufficiency
Addison Disease
Lupus Erythematosus
Proteinuria
Uremia
Bullous dermatitis herpetiformis
Helps manage Bullous dermatitis herpetiformis
Tuberculosis
Used to treat fulminating Tuberculosis in combination with Aminosalicylic acid
Serum Sickness
exfoliative erythroderma
Helps manage exfoliative erythroderma
Anemia, Diamond-Blackfan
Lupus
Congenital adrenal hyperplasia
Patient Participation
Tuberculosis
Used to treat Disseminated tuberculosis in combination with Aminosalicylic acid
Aspiration Pneumonitis
Drug Allergy
Asthma
Helps manage Asthma
Effectiveness
How Metreton Affects Patients
Allergies happen when an allergen (like pollen) interacts with and activates the antibodies on mast cells and basophils. This causes these cells to release histamine and other chemical mediators, which can cause itching, flushing, headaches, a racing heart rate, and other symptoms. Chlorpheniramine is a drug that works by blocking the histamine receptors in the body, which helps to reduce the symptoms of allergies like sneezing, runny nose, itchy eyes, and watery eyes.
How Metreton works in the body
Chlorpheniramine blocks the effects of histamine, which reduces the symptoms of allergies. It does this by attaching to the histamine H1 receptor and preventing it from responding to histamine.
When to interrupt dosage
The suggested measure of Metreton depends upon the determined condition, including upper respiratory indications, Coughing and Inflammation. The amount of dosage is contingent upon the administration technique (e.g. Kit; Syrup - Oral or Liquid - Oral) featured in the table beneath.
Condition
Dosage
Administration
Dermatomyositis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
prophylaxis of graves ophthalmopathy
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Craniotomy
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
exfoliative erythroderma
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Addison Disease
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
varicella-zoster virus acute retinal necrosis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Psoriasis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Trichinosis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
induction of Diuresis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Diuresis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Sarcoidosis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Brain
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Brain
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Optic Neuritis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Congenital adrenal hyperplasia
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Malignant Neoplasms
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
HIV Positive
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Red-Cell Aplasia, Pure
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Psoriatic Arthritis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Ulcerative Colitis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Tablet, delayed release - Oral, Tablet, delayed release, Kit, Solution, concentrate
Warnings
Metreton Contraindications
Condition
Risk Level
Notes
Mycoses
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Prednisone may interact with Pulse Frequency
There are 20 known major drug interactions with Metreton.
Common Metreton Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with Acteoside.
Metreton Toxicity & Overdose Risk
The lowest toxic dose of the drug for rats, mice, and guinea pigs has been found to be 306mg/kg, 130mg/kg, and 198mg/kg, respectively. It can also cause mild reproductive harm to women of childbearing age.
Metreton Novel Uses: Which Conditions Have a Clinical Trial Featuring Metreton?
163 active trials are currently underway to evaluate the potential of Metreton to reduce Allergy symptoms from vaccines, Eye issues, and Coughing.
Condition
Clinical Trials
Trial Phases
Drug Allergy
2 Actively Recruiting
Phase 3, Phase 2
Asthma
87 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Not Applicable, Phase 2, Phase 3
Tuberculosis
0 Actively Recruiting
Relapsing Polychondritis
1 Actively Recruiting
Phase 2
Giant Cell Arteritis
2 Actively Recruiting
Phase 1, Phase 2, Phase 3
Lupus
65 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1
Tennis Elbow
0 Actively Recruiting
Acute Coryza
0 Actively Recruiting
Ulcerative Colitis
17 Actively Recruiting
Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4
Bell Palsy
0 Actively Recruiting
Polymyalgia Rheumatica
3 Actively Recruiting
Phase 3, Phase 2
Patient Participation
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Chorioretinitis
0 Actively Recruiting
Acne Vulgaris
3 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Phase 4
Brain
7 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1
acute Bursitis
0 Actively Recruiting
Brain
0 Actively Recruiting
Arthritis, Juvenile
1 Actively Recruiting
Not Applicable
Bullous dermatitis herpetiformis
0 Actively Recruiting
Metreton Reviews: What are patients saying about Metreton?
5
Patient Review
11/4/2022
Metreton for Depression
5
Patient Review
10/11/2022
Metreton for Depression
5
Patient Review
11/4/2022
Metreton for Depression
5
Patient Review
10/11/2022
Metreton for Depression
5
Patient Review
11/4/2022
Metreton for Depression
5
Patient Review
10/11/2022
Metreton for Depression
4.7
Patient Review
9/26/2022
Metreton for Depression
4.7
Patient Review
9/26/2022
Metreton for Depression
4.7
Patient Review
9/26/2022
Metreton for Depression
4.3
Patient Review
10/20/2022
Metreton for Major Depressive Disorder
4.3
Patient Review
10/20/2022
Metreton for Major Depressive Disorder
4.3
Patient Review
10/20/2022
Metreton for Major Depressive Disorder
4
Patient Review
10/4/2022
Metreton for Major Depressive Disorder
4
Patient Review
8/18/2022
Metreton for Depression
4
Patient Review
10/4/2022
Metreton for Major Depressive Disorder
4
Patient Review
10/4/2022
Metreton for Major Depressive Disorder
4
Patient Review
8/18/2022
Metreton for Depression
4
Patient Review
8/18/2022
Metreton for Depression
1.7
Patient Review
9/13/2022
Metreton for Depression
1.7
Patient Review
9/13/2022
Metreton for Depression
1.7
Patient Review
9/13/2022
Metreton for Depression
1
Patient Review
8/13/2022
Metreton for Major Depressive Disorder
1
Patient Review
8/13/2022
Metreton for Major Depressive Disorder
1
Patient Review
8/13/2022
Metreton for Major Depressive Disorder
Patient Q&A Section about metreton
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.